Open Orphan: investment delivering social good

We strongly believe that it is possible to invest in companies that deliver social good — and be commercially successful. Open Orphan is a case in point. 

It is an honour and a privilege to be able to invest in companies that make this world a better place. A billion thanks to the hundreds of investors who have entrusted their savings with us, without whom this would simply not be possible. We invested in Open Orphan at the peak of the pandemic, in the 11p placing, to enable the company to conduct its human challenge studies for the testing of COVID-19 vaccines. Now the company is expanding into:

▪ Malaria: The company announced that it had developed a new human challenge study model for the testing of vaccines against malaria, which will be available to customers from November onwards. Malaria was responsible for over 400,000 deaths in 2019. That number should be zero.

▪ Asthma: Open Orphan won a contract worth £8m with one of the largest pharmaceutical companies in Britain to undertake human challenge studies on asthma sufferers, to test the impact of a new antiviral product. Asthma affects over 5.4 million people in the UK alone.

Video on the UK’s only COVID quarantine facility: www.openorphan.com/our-businesses/hvivo 

By reviewing www.UKCovidChallenge.com and www.flucamp.com investors can see first-hand where their money is invested.

Sterling Investments Management Ltd
Lynwood House 2-4 Crofton Road,
Orpington, England, BR6 8QE
info@sterlingim.co.uk

Write us a direct message using our